RxDoctor Payments Data

Umesh Narayanan, MD

Family Medicine · Sun City, AZNPI 1407239601

Payments from drug & device makers

$9,478in general payments, 2019–2025

Across 489 payments — averaging $19.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$825
  • GSK$762
  • AbbVie$641
  • Boehringer Ingelheim$617
  • Abbott$493
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$9,478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,478 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$365,862
Medicare patients
598
Services billed
4,894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin161$214,290
EliquisApixaban121$148,849
OzempicSemaglutide110$136,803
JanuviaSitagliptin Phosphate111$130,387
FarxigaDapagliflozin Propanediol78$86,595
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$82,886
XareltoRivaroxaban39$46,809
MyrbetriqMirabegron29$34,043
TrulicityDulaglutide13$23,574
TradjentaLinagliptin18$17,198
Repatha SyringeEvolocumab17$14,591
Rosuvastatin Calcium778$12,741
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$12,281
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$9,735
Levothyroxine Sodium867$9,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$617$231,487179 claims
PfizerEliquis$476$148,849121 claims
Novo NordiskOzempic$400$136,803110 claims
MerckJanuvia$156$130,387111 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$825$102,021103 claims
GSKTrelegy Ellipta$762$82,886103 claims
Johnson & JohnsonXarelto$146$46,80939 claims
Astellas Pharma US IncMyrbetriq$321$34,04329 claims
Lilly USA, LLCTrulicity$232$23,57413 claims
AbbVieSynthroid$641$4,95487 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Sun City

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →